ResearcherGerman Cancer Research CenterNo recent work listed
Frédérik Damm
Matched on ORCID iD 0000-0001-5553-1173; OpenAlex author ID A5046825627. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2020: 1 paper · 2021: 1 paper
Papers 2
- A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. Last author DOI 10.1016/j.ebiom.2021.103327↗
- TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO… Co-author DOI 10.1158/1078-0432.ccr-19-3034↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jana Käthe Striefler · 2 shared papers, 2020–2021 · strength 0.19
- Paper A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from … DOI 10.1016/j.ebiom.2021.103327↗
- Paper TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Gene… DOI 10.1158/1078-0432.ccr-19-3034↗
- Philipp Lohneis · 2 shared papers, 2020–2021 · strength 0.19
- Paper A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from … DOI 10.1016/j.ebiom.2021.103327↗
- Paper TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Gene… DOI 10.1158/1078-0432.ccr-19-3034↗
- Marianne Sinn · 2 shared papers, 2020–2021 · strength 0.19
- Paper A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from … DOI 10.1016/j.ebiom.2021.103327↗
- Paper TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Gene… DOI 10.1158/1078-0432.ccr-19-3034↗
- Uwe Pelzer · 2 shared papers, 2020–2021 · strength 0.19
- Paper A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from … DOI 10.1016/j.ebiom.2021.103327↗
- Paper TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Gene… DOI 10.1158/1078-0432.ccr-19-3034↗
- Hanno B. Riess · 2 shared papers, 2020–2021 · strength 0.19
- Paper A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from … DOI 10.1016/j.ebiom.2021.103327↗
- Paper TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Gene… DOI 10.1158/1078-0432.ccr-19-3034↗
- Kaja Hoyer · 1 shared paper, 2021 · strength 0.10
- Marcus Bahra · 1 shared paper, 2020 · strength 0.09
- Bruno Valentin Sinn · 1 shared paper, 2020 · strength 0.09
- Frederick Klauschen · 1 shared paper, 2020 · strength 0.09
- Rosa Bianca Schmuck · 1 shared paper, 2020 · strength 0.09
- Carsten Denkert · 1 shared paper, 2020 · strength 0.09
- Helmut Oettle · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.